Latest / Inside Startup Investing with Chris Lustrino
Re-Programming Viruses to Fight Brain Tumors—Inside Siren Biotechnology
On this week’s Inside Startup Investing, Dr. Nicole Paulk—founder & CEO of Siren Biotechnology—details her AAV gene-therapy “FedEx truck” that can deliver anti-tumor cytokines directly to brain cancers. Early animal data show 86 % complete responses; the FDA has signaled a fast-track path for Siren’s first-in-human trial set for 2026. With analog comps like Keytruda earning $30 B a year, Siren’s upside—and impact—could be enormous.
Highlights include...
Why viruses? AAV viruses don’t cause disease in humans yet efficiently deliver genetic payloads; Siren re-engineers them to express…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.